It might be more advantageous for scientists to produce a Middle East respiratory syndrome coronavirus vaccine for animals suspected to be part of the human transmission chain rather than develop a human vaccine, according to some infectious disease specialists. The cost and time involved in obtaining regulatory approval are limiting factors for human vaccine development, while animal vaccine development is more time- and cost-effective. Animal vaccines are an underused way to protect people from zoonotic disease, says physician Tom Monath, a founder of the One Health Initiative.

Full Story:

Related Summaries